Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis

Launched by LABORATOIRE INNOTECH INTERNATIONAL · Aug 1, 2015

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Patient with an abnormal vaginal discharge associated with one (or more) functional vaginal complaints: vaginal burning and/or vaginal pain and/or vaginal irritation clinically evoking an infectious vaginitis:
• • bacterial vaginitis
• • non-specific vaginitis (atypical symptoms)
• • mixed vaginitis (i.e. suprainfected fungal vaginitis) and able to receive an empirical local treatment
• Exclusion Criteria:
• • 1. Recurrent patient; i.e. a patient who has had at least 4 episodes of infectious vaginitis in the 12 months prior to inclusion
• • 2. Vaginal infection justifying systemic therapy
• • 3. History of atrophic vaginitis or suspected atrophic vaginitis at inclusion
• • 4. Patient presenting with signs of genital herpes or signs of non-infectious vulvar pathology (vulvodynia, psoriasis, eczema, lichen sclerosus, lichen planus, contact dermatitis, candida intertrigo, vulval intraepithelial neoplasia (VIN))
• • 5. Patient with current Sexually Transmitted Infection (STI) and/or patients with clinical suspicion of STI
• • 6. Disease or concomitant treatment that could cause decreased immunity (i.e. diabetes mellitus, corticosteroids treatments)
• • 7. Systemic anti-infective treatment (antibiotic, antifungal) within two weeks prior to inclusion
• • 8. Patient menstruating or patient with menometrorrhagia due to hormonal imbalance at the time of inclusion
• • 9. Pregnant or lactating women or delivery within last 1 month